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INTRODUCTION 
Rivastigmine is indicated for the treatment of mild to 
moderate dementia associated with Parkinson’s diseases. 
The dementia of Parkinson’s  disease is 
purportedly characterized by impairments in executive 
function, memory retrieval, and attention, in patients 
with an established diagnosis of Parkinson’s disease 3.  
Currently, oral solution (2mg/mL base), capsules (12 
mg/day) and transdermal dosage form (4.6mg/24h, 
9.5mg/24h and 13.3mg/24h) are approved in USA for the 
symptomatic treatment of mild to moderate AD
 3, 4
. 
Analysis of data from the clinical trial investigation 
suggested that rivastigmine may also benefit patients 
even at more advance stages of diseases
 5
. Increased 
dosing frequency of twice a day dosage regimen, GI side 
effects associated with the large fluctuation in the plasma 
level limits its usage
 6
; hence need for once a day 
controlled release formulation of rivastigmine which will 
reduce the larger fluctuation in plasma level and thereby 
increasing patient’s compliance. 
MATERIALS AND METHODS: 
Materials 
Rivastigmine tartrate is obtained from Orchid 
Healthcare, Hydroxy propylmethylcellulose (HPMC K 
Methocel 100M) and polyethylene oxide (Polyox 
WSR303) was obtained from Colorcon Asia Private 
Limited (India), Microcrystalline cellulose (Avicel PH 
112) is received from signet Chemical Corporation 
Private Limited (Mumbai, India),  Colloidal silicon 
dioxide (Aerosil 200) was purchased from Evonik 
Industries (Mumbai, India) and  Magnesium stearate 
(vegetable source) was purchased from Ferro corporation 
(Cleveland, USA).All other chemicals and reagents used 
were of high analytical grade.  
Methods 
Manufacturing procedure of CR tablets of 
Rivastigmine 
Based on the simulated dose calculation the required 
quantity of Rivastigmine tartrate is taken in the unit 
composition of the controlled release formulation of 
Rivastigmine tartrate and is represented in the table-1.   
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ABSTRACT: 
Rivastigmine, an Anti-Alzheimer’s drug suffer from a major limitation of sever GI adverse events such as nausea, vomiting, 
diarrhea, loss of appetite, weight loss and increase dosing frequency 1. The present work aim at design, optimization and 
development of rivastigmine once a day controlled release formulation to minimize the above limitation and increase patient’s 
compliance. Based on the target in-vitro release profile derived from pharmacokinetic simulation 2, a once a day matrix tablet 
with the simulated dose was developed. The simple direct compression process was followed as a manufacturing process, the 
percentage of Polymer HPMC K100M, Polyethylene oxide (Polyox WSR303) and insoluble excipients microcrystalline 
cellulose used in the formulation were optimized using 23 full factorial design. The formulations were then evaluated for the 
physical characteristics of blend, tablets, swelling index, percentage of erosion, drug release and release rate kinetics. The 
quadratic model was suggested, contour and 3D graphs were generated. The optimized formulation was subjected to stability 
studies. The final optimized formulation showed a comparative release profile similar to that the desired in-vitro target release 
profile, which followed zero order release kinetics  and a stable formulation. 
Keywords: Controlled Release Formulation, Rivastigmine Tartrate, HPMC K100M, Polyethylene oxide (Polyox WSR303), 
microcrystalline cellulose 
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Table 1: Manufacturing Formula 
S.No Ingredients /Specification Qty/Unit (mg) Percentage (%) 
01 Rivastigmine tartrate USP 17.4$ 8.7 
02 Anhydrous lactose NF (Supertab 21AN) # # 
03 Microcrystalline cellulose NF (Avicel PH112) 27.5 – 47.5 13.75 –  23.75 
04 Hydroxy propylmethylcellulose USP (Methocel 
K100M) 
60 – 100 30 – 50 
05 Polyethylene oxide NF (Polyox WSR 303) 20 – 28 10 – 14 
06 Colloidal silicon dioxide NF (Aerosil 200M) 2.0 1 
07 Magnesium Stearate NF (Vegetable source) 1.5 0.75 
Total (mg) 200  
$ - Qty of rivastigmine tartrate equivalent to rivastigmine 10.9 mg 
# - Qty of anhydrous lactose to be adjusted based on the potency of rivastigmine tartrate and in-order to maintain the constant 
average weight. 
 
The controlled release matrix tablets of rivastigmine 
were prepared by a simple direct compression process. 
Step: 1 Rivastigmine, Polyethylene oxide (WSR 303) 
and microcrystalline cellulose (Avicel PH 112) are 
weighed accurately and sifted together through #30 
ASTM sieve. 
Step: 2  Hydroxypropyl methylcellulose (HPMC, 
Methocel K100M)) and lactose anhydrous (Supertab 21 
AN) are weighed accurately and sifted together through 
#30 ASTM sieve mesh. 
Step: 3 The material of Step 1 and Step 2 are blended in 
a double cone blender for 20 minutes. 
Step: 4 The weight quantity of colloidal silicon dioxide 
(Aerosil 200) and magnesium stearate are sifted 
together through # 60 mesh. 
Step: 5  The material of step 3 is lubricated with step 4 
material by blending for 10 minutes in a double cone 
blender. 
Step: 6  The above step 5 material is compressed into 
tablets using 8.1 mm circular flat faced beveled edge 
tooling.  
Optimization of quantity of Polymers Hypromellose 
(HPMC), polyethylene oxide (PEO) and insoluble 
filler microcrystalline cellulose using 2
3
 full factorial 
design: 
A 2
3
 full factorial design was selected to optimize three 
variables viz., rate controlling polymer Hypromellose 
(HPMC), matrix forming polymer polyethylene oxide 
(PEO) and an insoluble filler microcrystalline cellulose 
(Avicel PH112). In these 2
3
 full factorial design each 
variables were evaluated at 2 levels and experimental 
trails were conducted for all possible 8 combinations 
and a triplicate centre point run was also executed to 
determine the signal to noise ratio. The response was 
analyzed for ANOVA using Design Expert, Stat-Ease, 
Inc, version 9.0.1.0. A mathematical equation was 
generated for each response parameter. The 
mathematical models were tested for significance. 
Response surface plots were generated for response to 
study the behavior of the system. The 2
3
 full factorial 
design for factorial batches are presented in the Table -2 
Table 2: 2
3
 full factorial design for factorial batches: 
Run 
Order 
Formulation 
code 
Variable in coded form Factor 1 Factor 2 Factor 3 
Factor 1 Factor 2 Factor 3 
A 
Hypermellose 
(mg) 
B 
Polyethylene 
oxide (mg) 
C 
Microcrystalline 
cellulose (mg) 
1 RIV-CR/001 +1 +1 +1 100 28 47.5 
2 RIV-CR/002 -1 -1 -1 60 20 27.5 
3 RIV-CR/003 0 0 0 80 24 37.5 
4 RIV-CR/004 -1 +1 -1 60 28 27.5 
5 RIV-CR/005 0 0 0 80 24 37.5 
6 RIV-CR/006 +1 +1 -1 100 28 27.5 
7 RIV-CR/007 -1 +1 +1 60 28 47.5 
8 RIV-CR/008 0 0 0 80 24 37.5 
9 RIV-CR/009 +1 -1 +1 100 20 47.5 
10 RIV-CR/010 -1 -1 +1 60 20 47.5 
11 RIV-CR/011 +1 -1 -1 100 20 27.5 
 
Determination of Physical characteristic of Blend: 
The interparticulate interactions that influence the 
bulking properties of a powder are also the interactions 
that interfere with powder flow, a comparison of the bulk 
and tapped densities can give a measure of the relative 
importance of these interactions in a given powder. Such 
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a comparison is often used as an index of the ability of 
the powder to flow
 7
.   
Bulk density and Tap density:  
Bulk density is determined by measuring the volume of a 
known mass of powder sample that has been passed 
through a screen into a graduated cylinder (Method I). 
An accurately weighed (M) quantity of powder is poured 
into the graduate measuring cylinder and carefully the 
powder is leveled without compacting. The unsettled 
apparent volume (Vo) to the nearest graduated unit is 
measured. The bulk density is expressed in g per mL 
(Eq.1) and is measured in replicate. 
𝐵𝑢𝑙𝑘 𝐷𝑒𝑛𝑠𝑖𝑡𝑦 =
𝑀𝑎𝑠𝑠  (𝑀)
𝑉𝑜𝑙𝑢𝑚𝑒  (𝑉𝑜)
 (Eq.1) 
Tap density is determined by mechanically tapping the 
cylinder containing powder sample.  After observing the 
initial volume (Vo), the cylinder is mechanically tapped 
using Electrolab tap density apparatus (ETD-1020, 
Electrolab India) and the volume reading are taken until 
little further volume changed is observed. (i.e) final 
tapped volume (Vf). The tap density is expressed in g per 
mL (Eq.2) and is measured in replicate.  
𝑇𝑎𝑝 𝐷𝑒𝑛𝑠𝑖𝑡𝑦 =
𝑀𝑎𝑠𝑠  (𝑀)
𝑉𝑜𝑙𝑢𝑚𝑒  (𝑉𝑓)
 (Eq.2) 
Measure of Powder Compressibility: 
The Compressibility Index and Hausner Ratio are 
measures of the propensity of a powder to be 
compressed. As such, they are measures of the relative 
importance of interparticulate interactions. In a free-
flowing powder, such interactions are generally less 
significant, and the bulk and tapped densities will be 
closer in value. For poorer flowing materials, there are 
frequently greater interparticle interactions, and a greater 
difference between the bulk and tapped densities will be 
observed. These differences are reflected in the 
Compressibility Index and the Hausner’s Ratio 
represented by the equation 3 and 4 respectively. 
𝐶𝑜𝑚𝑝𝑟𝑒𝑠𝑠𝑖𝑏𝑖𝑙𝑡𝑦 𝐼𝑛𝑑𝑒𝑥 =
100 (𝑉𝑜  −  𝑉𝑓)
𝑉𝑜
   (Eq.3) 
𝐻𝑎𝑢𝑠𝑛𝑒𝑟′𝑠 𝑅𝑎𝑡𝑖𝑜 =
𝑉𝑜
𝑉𝑓
   (Eq.4)  
The compressibility index (Carr’s Index) values are 
represented in the scale of flowability table 3 
Table 3: Scale of flowability 
Evaluation of Controlled Release Matrix Tablets of 
Rivastigmine tartrate 
8, 9
: 
Weight Variation: The representative twenty tablets 
samples from each formulation trails were weight using 
balance (MIRAS, Sartorius Mechatronics India, Pvt ltd). 
The average weight and standard deviation are calculated 
and are represented in the table-4. 
Thickness: The representative ten tablets samples from 
each formulation trails were measured using (VK200, 
Varian Inc, Cary, NC, USA). The average thickness and 
standard deviation are calculated and are represented in 
the table-4. 
Hardness: The representative ten tablets samples from 
each formulation trails were measured using (VK200, 
Varian Inc, Cary, NC, USA). The average hardness and 
standard deviation are calculated and are represented in 
the table-4. 
Friability Test:  The whole tablets corresponding as 
near as possible to 6.5 g were taken from each 
formulation trails and are dedusted prior to testing. 
Accurately weighed tablets are placed in the drum of 
friabilator (EF-2, Electrolab, Mumbai, India) and the 
apparatus is operated at 25 rpm for 4 minutes (i.e., 100 
revolutions). The tablets were then dedusted and 
reweighed. The friability is calculated as a percentage 
weight loss and is represented by the equation (Eq 5). 
The friability observed is represented in the table -4. 
𝐹𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (% 𝑤/𝑤) =
𝑊1−𝑊2
𝑊1
x100  (Eq.5) 
Whereas, 
W1 – Weight of Initial tablets 
W2 – Weight of final tablets after 100 revolution.  
Swelling and Erosion: 
A Swelling and matrix erosion study was performed as 
per the method reported 
10, 11
. The matrix tablets from the 
(B.No: RIV-CR/003) center point formulation trial (n=3) 
were subjected to dissolution using USP type –II 
(paddle) (Disso 2000, Lab India). The accurately weight 
tablets (W1) are dropped into the dissolution vessel 
containing 500 mL of purified water, paddle rotated at 50 
rpm and maintained at a temperature of 37°C±0.5°C.  At 
selected time intervals over a period of 24 hours, the 
swollen /hydrated tablets were removed carefully and 
wiped gently to remove surface water and weighed (W2). 
The matrix erosion is determined by weighing swollen / 
hydrated tablets and is then subjected to drying in an 
oven at a temperature of about 60°C until a constant 
mass was achieved to determine the weight loss (W3). 
The swelling index and matrix erosion are calculated 
using the equation 6 & 7. 
 
Swelling Index  % =
𝑊𝑒𝑖𝑔𝑕𝑡  𝑜𝑓𝑠𝑤𝑜𝑙𝑙𝑒𝑛  𝑡𝑎𝑏𝑙𝑒𝑡  𝑎𝑡  𝑠𝑝𝑒𝑐𝑓𝑖𝑒𝑑  𝑡𝑖𝑚𝑒  𝑖𝑛𝑡𝑒𝑟𝑣𝑎𝑙   𝑊2 –𝐼𝑛𝑖𝑡𝑖𝑎𝑙  𝑤𝑒𝑖𝑔 𝑕𝑡  𝑜𝑓  𝑡𝑎𝑏𝑙𝑒𝑡   𝑊1 
𝐼𝑛𝑖𝑡𝑖𝑎𝑙  𝑤𝑒𝑖𝑔 𝑕𝑡  𝑜𝑓  𝑡𝑎𝑏𝑙𝑒𝑡   𝑊1 
 x 100 (Eq.6) 
Erosion  % =
𝐼𝑛𝑡𝑖𝑎𝑙  𝑤𝑒𝑖𝑔 𝑕𝑡  𝑜𝑓  𝑡𝑎𝑏𝑙𝑒𝑡   𝑊1  –𝑊𝑒𝑖𝑔𝑕𝑡  𝑜𝑓  𝑡𝑎𝑏𝑙𝑒𝑡  𝑎𝑓𝑡𝑒𝑟  𝑑𝑟𝑦𝑖𝑛𝑔   𝑊3 
𝐼𝑛𝑖𝑡𝑖𝑎𝑙  𝑤𝑒𝑖𝑔 𝑕𝑡  𝑜𝑓  𝑡𝑎𝑏𝑙𝑒𝑡   𝑊1 
 x 100 (Eq.7) 
Flow 
Characteristics 
Compressibility 
Index (%) 
Hausner’s 
ratio 
Excellent ≤ 10 1.00 – 1.11 
Good 11 – 15 1.12 – 1.18 
Fair 16 – 20 1.19 – 1.25 
Passable 21 – 25 1.26 – 1.34 
Poor 26 – 31 1.35 – 1.45 
Very  poor 32 – 37 1.46– 1.59 
Very, very poor > 38 > 1.60  
Abdul Razack et al                                   Journal of Drug Delivery & Therapeutics. 2014; 4(6):58-67  61 
© 2011-14, JDDT. All Rights Reserved                                                  ISSN: 2250-1177                                              CODEN (USA): JDDTAO 
In vitro dissolution studies  
The invitro dissolution studies were carried out using 
USP –II (Paddle), with 500mL of purified water as 
dissolution media and at stirring speed of 50 rpm of 
paddle (Lab India dissolution apparatus, 2000 series). 
The tablets were placed in a dissolution vessel 
containing media, maintained at a temperature of 
37°C±0.5°C. A 5mL of sample is collected at 
appropriate time interval (2, 4, 6, 12, 15, 20 and 24 
hours) from the dissolution vessel and then replaced 
with equivalent volume of dissolution media in order to 
maintain the constant volume (sink condition).  The 
samples were then analyzed using validated HPLC 
method 
12
.   
Drug Release Kinetics 
13
    
        
The invitro drug release data of a few selected batches 
were tested with the help of DD solver, for the 
mathematical model such as zero-order, first order, 
Higuchi, Korsmeyer-Peppas and Hixson-Crowell 
equations.  
Zero-order equation: 
The equation is used to represent the dissolution of drug 
from the dosage form that do not disintegrate and 
release the drug slowly. 
Qt = Q0 - K0t   (Eq 8) 
Where Qt is the amount of drug dissolved in time t, Q0 is 
the initial amount of drug in solution (most of time 
Q0=0) and K0 is the zero order rate constant expressed 
in unit concentration /time. A graph of concentration vs 
time would yield a straight line with a slope equal to K0 
and intercept the origin of the axes. 
First order equation 
14
: 
The release behavior of first order equation expressed 
as follows,  
Log Qt= Log Q0 + K1t / 2.303    (Eq 9) 
Where Qt is the amount of drug released in time t, Q0 is 
the initial amount of drug in the solution and K1 is the 
first order release constant. A graph of log cumulative 
percentage of drug remaining vs time yields a straight 
line with a slope of –K / 2.303. 
Higuchi Model 
15
 
The Higuchi model describes drug release as a diffusion 
process based on the Fick’s law, square root time 
dependent. The equation is as follows, 
Q = K 𝑡    (Eq 10) 
Where Q is the amount of drug dissolved at time t, K is 
the constant reflecting the design variables of the 
system. The data obtained were plotted as cumulative 
percentage drug release versus square root of time. 
Hixson-Crowell Model 
16
 
The equation describes the release from systems where 
there is a change in surface area and diameter of 
particles or tablets. The particles regular area is 
proportional to the cube root of its volume. The 
equation is expressed as follows, 
W0 
1/3
 - Wt 
1/3
 = κ t (Eq 11) 
Where W0 is the initial amount of drug in the dosage 
form, Wt is the remaining amount of drug in the dosage 
form at time t and k (kappa) is a constant incorporating 
the surface-volume relation. A graphic of the cubic root 
of the drug percentage remaining in the matrix versus 
time is plotted. 
 Korsmeyer – Peppas Equation 17 
The mechanism of drug release can be determined using 
the well known exponential equation  
Log (Mt/Mf) = Log k + n Log t   (Eq 12) 
Where Mt is the amount of drug released at time t; Mf 
is the amount of drug released after infinite time; k is a 
release rate constant, incorporating structural and 
geometric characteristics of the tablet; and n is the 
release exponent indicative of the mechanism of drug 
release. Each formulation data are plotted as log 
percentage of drug dissolved verses log time. 
 If  n = 0.45 indicates Fickian diffusion 
 If 0.45<n<0.89 indicates anomalous diffusion or 
non- Fickian diffusion.   
 If n = 0.89 and above indicates case-2 relaxation or 
super case transport-2. 
 Anomalous diffusion or non-fickian diffusion 
refers to combination of both diffusion and erosion 
controlled rate release. 
 Case-2 relaxation or super case transport-2 refers to 
the erosion of the polymeric chain.    
Stability Studies 
The stability studies were carried out as per 
International conference on Harmonization (ICH) 
guidelines 
[18]
. The optimized formulation (RIV-
CR/003) is packed in HDPE bottle and is charged in 
stability chamber (Newtronic, India) both Accelerated 
(40°C/75 % RH) and long term condition 
(25°C/60%RH). The stability samples are then 
evaluated for Assay, Water content, dissolution and 
related substances. 
Results and Discussion 
Determination of Physical characteristic of Blend: 
The final blend of the various formulation trials of 
matrix tablet were characterized with respect to bulk 
density, tap density, compressibility index and 
Hausner’s ratio. Thus all the batches indicate good to 
fair flow properties and found to be suitable for a direct 
compression process of final blend. The results are 
presented in the table-4. 
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Table 4: Physical characteristics of Blend: 
Formulation 
Trials 
Bulk density 
(g/mL) 
Tap density (g/mL) 
Compressibility 
Index (%) 
Hausner’s Ratio 
RIV-CR/001 0.37 0.51 27.2 1.4 
RIV-CR/002 0.43 0.60 27.5 1.4 
RIV-CR/003 0.41 0.52 21.6 1.3 
RIV-CR/004 0.43 0.54 20.0 1.3 
RIV-CR/005 0.38 0.47 19.0 1.2 
RIV-CR/006 0.38 0.48 21.3 1.3 
RIV-CR/007 0.39 0.51 22.4 1.3 
RIV-CR/008 0.39 0.51 22.4 1.3 
RIV-CR/009 0.37 0.45 19.5 1.2 
RIV-CR/010 0.38 0.49 21.8 1.3 
RIV-CR/011 0.43 0.52 15.9 1.2 
 
Evaluation of Controlled Release Matrix Tablets of Rivastigmine
 
The each formulation trials were evaluated for parameters such as weight variation, thickness, hardness and friability. 
The weight variation was found to be within ± 5% and the results are represented in the table-5 
Table 5: Physical characteristics of Matrix Tablet 
Formulation Trials 
Weight Variation  
(n =20) 
Thickness (mm) 
(n=10) 
Hardness (kP) ± SD 
(n=10) 
Friability 
(%w/w) 
RIV-CR/001 198.6 ± 2.3 3.62 8.6 ± 0.6 0.02 
RIV-CR/002 201.8 ± 1.6 3.31 10.6 ± 1.1 0.01 
RIV-CR/003 203.8 ± 3.0 3.47 9.9 ± 0.9 0.02 
RIV-CR/004 202.5 ± 2.1 3.39 9.3 ± 1.0 0.02 
RIV-CR/005 200.2 ± 1.7 3.40 10.2 ± 0.9 0.01 
RIV-CR/006 201.7 ± 2.1 3.46 11.7 ± 0.9 0.03 
RIV-CR/007 203.7 ± 3.0 3.46 9.8 ± 0.8 0.01 
RIV-CR/008 200.6 ± 2.0 3.36 11.2 ± 0.9 0.01 
RIV-CR/009 202.3 ± 2.8 3.60 9.0 ± 0.5 0.01 
RIV-CR/010 203.5 ± 3.8 3.42 9.4 ± 1.0 0.02 
RIV-CR/011 201.5 ± 1.5 3.43 11.5 ± 1.0 0.03 
 
Swelling and Erosion: 
The swelling of polymer occurs upon hydration, and 
causes increase in hydrodynamic volume as the mobility 
of the polymer increases 
[19]
. The swelling profile of the 
center point formulation trial (B.No: RIV-CR/003) was 
found to be very rapid up to 6 hours and there after 
shows constant swelling index. The swelling index and 
matrix erosion profile of the Rivastigmine tartrate 
controlled release formulation is presented in the figure -
1 and figure-2 below. 
 
 
Figure 1:  Swelling index Profile of the Controlled release formulation of Rivastigmine tartrate. 
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Figure-2:  Matrix Erosion Profile of the Controlled release formulation of Rivastigmine tartrate. 
 
Based on the above data the center point formulation 
trial (RIV-CR/003) showed a swelling index of 500 % 
and erosion of the matrix was observed to be 50 %. 
In vitro drug release study:  
The observed dissolution results and the similarity value 
(F2) of all the formulation trials as per experimental 
design are presented in the table- 6. The formulations 
trial (B.No: RIV-CR/002) showed higher drug release 
due to the lower amount of rate controlling polymers 
and the formulation trial (B.No: RIV-CR/001) showed 
lower drug release due to higher amount of rate 
controlling polymers. The figure -3 shows the drug 
release profile of the three formulation trials in 
comparison with the target release profile.  Similarly the 
F2 value fails for the formulation with lower and higher 
amount of rate controlling polymer failed to compile the 
acceptable limit of ≥ 50 %.  
 
Table 6: In-vitro release data of all formulations trials as per experimental design: 
Time 
in 
hrs 
Formulation Trials 
RIV-
CR/00
1 
RIV-
CR/00
2 
RIV-
CR/00
3 
RIV-
CR/00
4 
RIV-
CR/00
5 
RIV-
CR/00
6 
RIV-
CR/00
7 
RIV-
CR/00
8 
RIV-
CR/00
9 
RIV-
CR/01
0 
RIV-
CR/01
1 
In 
vitro 
target 
release 
Cumulative percentage of drug release 
2 hr 2.1 22.3 12.4 7.2 10.2 5.6 8.2 11.8 16.5 20.5 17.4 8.9 
4 hr 8.2 46.5 16.8 18.2 19.1 11.5 22.5 17.5 22.7 41.3 20.1 17.7 
6 hr 13.2 51.1 33.3 33.6 30.2 14.6 33.3 31.5 30.1 47.6 34.6 26.6 
12 hr 33.9 62.3 49.0 63.5 45.9 36.3 58.5 47.1 40.3 60.6 48.6 53.2 
15 hr 52.7 82.3 69.3 88.6 65.8 51.9 79.9 67.8 65.9 84.6 70.2 66.4 
20 hr 73.9 99.9 90.2 100.0 87.1 79.8 100.2 88.9 85.9 97.6 88.9 88.6 
24 hr 88.5 99.9 98.8 101.2 99.7 89.3 101.3 101.1 96.2 102.4 95.7 100 
F2 
valu
e 
43.87 38.18 71.68 48.69 73.60 47.42 55.49 73.56 59.55 40.94 63.43 -- 
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Figure 3: Drug release profile comparison of trial formulation with the target release profile. 
ANOVA of quadratic model for percentage drug 
release 
ANOVA table was used to generate mathematical 
models. The high values of correlation coefficient for 
percentage of drug loaded indicate a good fit i.e. good 
agreement between the selected factor and response. The 
mathematical model was evolved by omitting 
insignificant term (p > 0.05). So, the main effect A and B 
were found significant as p value was < 0.05. The 
ANOVA response table for the quadratic model is 
presented in the Table no: 7 & 8 for the dissolution 
response at the initial phase of release (2hr) and the 
terminal phase of release (20 hr) 
 
Table 7: ANOVA for selected factorial model for 2 hours of dissolution response 
Analysis of variance table [Partial sum of squares - Type III] 
 
Sum of 
 
Mean F p-value 
 Source Squares df Square Value Prob > F 
 Model 393.565 2 196.7825 120.655 3.76E-06 significant 
  A-Polymer K100 M 34.445 1 34.445 21.11956 0.002497 
   B-PEO WSR -303 LEO 359.12 1 359.12 220.1904 1.51E-06 
 Curvature 2.218333 1 2.218333 1.360146 0.281705 
 Residual 11.41667 7 1.630952 
   Lack of Fit 8.83 5 1.766 1.365464 0.473918 not significant 
Pure Error 2.586667 2 1.293333 
   Cor Total 407.2 10 
     
Table 8: ANOVA for selected factorial model for 20 hours of dissolution response 
Analysis of variance table [Partial sum of squares - Type III] 
 
 
Sum of 
 
Mean F p-value 
 Source Squares df Square Value Prob > F 
 Model 711.705 3 237.235 48.34985 0.000135 Significant 
  A-Polymer K100 M 598.58 1 598.58 121.994 3.28E-05 
   B-PEO WSR -303 LEO 42.32 1 42.32 8.625059 0.026054 
   AB 70.805 1 70.805 14.43046 0.008981 
 Curvature 8.946818 1 8.946818 1.823413 0.225614 
 Residual 29.4398 6 4.906633 
   Lack of Fit 24.57 4 6.1425 2.522691 0.303469 not significant 
Pure Error 4.8698 2 2.4349 
   Cor Total 750.0916 10 
     
Higher level of 
polymers (RIV-
CR/001)
Higher level of 
polymers (RIV-
CR/001)
Lower level of 
polymers (RIV-
CR/002)
Optimum level of 
polymers (RIV-
CR/003)
Target
Target
0
10
20
30
40
50
60
70
80
90
100
0 4 8 12 16 20 24
C
u
m
u
la
ti
ve
 %
 o
f 
d
ru
g 
re
le
as
e
Time in hrs
Higher level of polymers (RIV-
CR/001)
Lower level of polymers (RIV-
CR/002)
Abdul Razack et al                                   Journal of Drug Delivery & Therapeutics. 2014; 4(6):58-67  65 
© 2011-14, JDDT. All Rights Reserved                                                  ISSN: 2250-1177                                              CODEN (USA): JDDTAO 
Factorial equation for percentage of drug loaded in 
terms of coded factors: 
Dissolution at 2 hr = 12.2 – 2.075 *A – 6.7 *B 
Dissolution at 20 hr = 90.22273 – 8.65 *A – 2.3*B– 
2.975*AB 
Response surface plots for the percentage of Invitro 
drug release: 
The counter plot and 3D plot shows the effect of ratio of 
significant factor such as polyethylene oxide (Polyox 
WSR 303 and Hypromellose (HPMC K100M) on 
percentage of drug release at 2 hours (initial phase of 
release) and at 20 hours (terminal phase of drug 
release). As the concentration of polyethylene oxide 
(Polyox WSR 303) increases the percentage of drug 
release at 2 hours decreases significantly, probably due 
the higher rate of hydration and swelling of the 
polymer. Whereas the increase in concentration of 
Hypromellose (HPMC K100M) showed significant 
lower dissolution at the terminal phase of drug release 
(20 hours), which may be probably due to higher gel 
strength of matrix.  The counter plot and 3D plot at 
initial release (2 hrs) and at terminal phase of release 
(20 hrs) are represented in the figure 4, 5, 6 and 7.
 
 
Figure: 4 Contour plot of % of Drug Release at 2 hours. 
 
Figure: 5 Contour plot of % of Drug Release at 20 hours. 
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Figure: 6 3D Graph of % of Drug Release at 2 hours. 
 
Figure: 7 3D Graph of % of Drug Release at 20 hours. 
 
Drug Release Kinetics: 
The drug release data of few selected batches were fitted 
to Zero-order, fist order, Higuchi, Korsmeyer-Peppas and 
Hixson-Crowell equations and release kinetic data of the 
batches are presented in table -9. The batch with higher 
amount of rate controlling polymers (RIV-CR/001) and 
optimum quantity of rate controlling polymer (RIV-
CR/003) showed best R
2
 value fit for Zero order release 
model, whereas the release mechanism of drug transport 
for higher amount of rate controlling polymer was found 
to be erosion of polymeric chain with super case-2 
transport and batch with optimum quantity of rate 
controlling polymers showed both diffusion and erosion 
controlled rate of release with an anomalous diffusion or 
Non-Fickian diffusion mechanism of drug transport. The 
batches with lower level of rate controlling polymer 
(RIV-CR/002) showed best R
2
 value fit for first order 
release model with a near fickian diffusion mechanism of 
drug transport.  
 
Table 9: Mathematical Modeling and drug release kinetics of controlled release formulation of Rivastigmine tartrate. 
Batch 
No 
Rate controlling 
polymer 
Zero-
order 
First 
Order 
Higuchi 
Korsmeyer-
Peppas 
Hixson-
Crowell 
n 
Mechanism of 
drug transport 
RIV-
CR/001 
High 0.9680 0.8992 0.7255 0.9886 0.9047 1.249 
super case-2 
transport 
RIV-
CR/002 
Low 0.6550 0.9254 0.9560 0.8698 0.9140 0.442 
Near 
Fickian diffusion 
RIV-
CR/003 Center 0.9811 0.9175 0.8558 0.9691 0.9541 0.871 
Anomalous 
diffusion or Non 
Fickian diffusion 
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Stability Studies 
The optimized center point formulation trial (RIV-
CR/003) is subjected to stability studies as per ICH (i.e) 
both at accelerated (40°C/75 % RH) and long term 
condition (25°C/60%RH) for a period of 6 months 
showed a stable formulation with no significant change 
in the Assay, water content, dissolution and related 
substances as compared to initial. 
CONCLUSION: 
A 2
3
 full factorial design was applied to arrive at an 
optimized once daily controlled release formulation of 
rivastigmine tartrate with an invitro release profile 
similar to that of the target release profile which was 
derived from the pharmacokinetic simulations. The 
factorial design provided details of the influence of 
independent factors on the response. The results of 
analysis of variance showed that two independent 
variables viz, polyethylene oxide (Polyox WSR303) and 
hypermellose (Methocel K100M) had significant effect 
on the selected response at the initial phase and terminal 
phase of drug release respectively. It is thus concluded 
that by adopting a systematic approach, an optimum 
point can be reached in the shortest time with minimum 
efforts. Stability study indicated that the optimized batch 
was stable as per ICH stability testing conditions. Hence 
the once a day controlled release formulation of 
rivastigmine tartrate shall provide improved patients 
compliance by reducing GI adverse effects and dosing 
frequency.
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